Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Henry Thomason

Orthopaedic Surgery Gastonia, NC Medical Doctor

NPI 1841266301 CMS profile 356579

2345 Court Drive, Gastonia, NC 28054

Open in the dashboard

General payments

$57,446

140 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$107,149 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Henry Thomason of Gastonia, NC is reported in the CMS Open Payments database as having received $57,446 across 140 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $107,149 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 90th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $23,587 27
2024 General $9,783 22
2023 General $8,734 22
2022 General $11,871 28
2021 General $351 10
2020 General $167 8
2019 General $2,953 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Henry Thomason
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Henry Thomason were reported at $23,587. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Henry Thomason Orthopaedic Surgery median Middle half National median
2019 $2,953 $644 $140–$2,844 $163
2020 $167 $312 $75–$1,860 $114
2021 $351 $520 $117–$2,495 $132
2022 $11,871 $598 $128–$2,731 $149
2023 $8,734 $461 $128–$2,264 $160
2024 $9,783 $497 $134–$2,475 $164
2025 $23,587 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Heron Therapeutics, Inc. $51,059 44 payments
  2. Zimmer Biomet Holdings, Inc. $3,555 15 payments
  3. DePuy Synthes Sales Inc. $650 13 payments
  4. Stryker Corporation $565 12 payments
  5. Peerless Surgical Inc. $314 3 payments
  6. Fidia Pharma USA Inc. $175 6 payments
  7. Flexion Therapeutics, Inc. $173 8 payments
  8. Radius Health, Inc. $144 6 payments
  9. Orthalign Inc $114 1 payment
  10. Medical Device Business Services, Inc. $109 2 payments
  11. Other $588 30 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $36,988 15 payments
  2. Travel and Lodging $8,233 14 payments
  3. Consulting Fee $7,874 9 payments
  4. Food and Beverage $4,352 102 payments
Products named General payments · program years 2019–2025
  1. ZYNRELEF Post Surgical Pain Relief $39,696 31 payments
  2. Zynrelef Postoperative Pain $11,363 13 payments
  3. APONVIE $9,156 5 payments
  4. Surgical Product Portfolio $1,375 3 payments
  5. Surgical Instruments $625 1 payment
  6. PI Surgical $500 1 payment
  7. ZIPSEAL 16 SURGICAL SKIN CLOSURE KIT $354 2 payments
  8. Persona $280 2 payments
  9. NA $243 3 payments
  10. mymobility Platform $230 2 payments
  11. Other $2,728 94 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

2,124

Median for Orthopedic Surgery: 203

Drug cost

$16,616

Median for Orthopedic Surgery: $1,433

Branded share of claims

12.2%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone Hcl Generic 782 $5,559
Eliquis Apixaban Brand 11 $4,138
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 191 $2,079
Cefadroxil Generic 212 $1,036
Celecoxib Generic 60 $694
Amoxicillin Generic 240 $444
Mupirocin Generic 46 $415
Clindamycin Hcl Generic 96 $320
Methylprednisolone Generic 57 $313
Tramadol Hcl Generic 96 $273

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 76 billing codes

Paid by Medicare

$292,030

Of which drugs: $47,306

Medicare patients

484

Average age 75

Services billed

5,962

309 women, 175 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 35%
Chronic kidney disease 29%
Depression 28%
Ischemic heart disease 24%
Cancer 18%
Heart failure 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, hymovis, for intra-articular injection, 1 mg J7322 Office 43 2,832 $38,248
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 157 500 $2,487

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Tymlos
  • Radius Health, Inc. $45
$45 — —
PROLATE
  • Forte Bio-Pharma LLC $13
$13 — —
Zilretta
  • Pacira Pharmaceuticals Incorporated $4
$4 — —
Exparel
  • Pacira Pharmaceuticals Incorporated $4
$4 — —
NALOCET
  • Forte Bio-Pharma LLC $3
$3 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

140 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record